Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer (PICASSO)

Institute of Hospitalization and Scientific Care (IRCCS)

Status: Enrolling

Conditions: Small Cell Lung Cancer

Treatments: Drug: Atezolizumab

Study type: Observational

Funder types: Other

Identifiers

NCT05797493

5061

Details and patient eligibility

About

The scope of the PICASSO project is to apply an innovative patient-based pan-omic approach to immune-assays, that will include multi-omics tumour characterization (genome, proteome, transcriptome), blood immune-cells and cytokine profiling, serological screening for paraneoplastic autoantibodies, clinical and metabolic measurements.

The PICASSO project is aimed to validate in real world population the predictive role of SCLC transcriptomic classification (particularly, I-SCLC subtype) and to explore correlations with dynamic changes in peripheral blood immunity. Additionally, investigators expected to validate the predictive/prognostic role of emerging new variables, including metabolic-induced meta-inflammation alterations and subclinical auto-immunity.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. histologically- or cytologically-documented extensive-stage SCLC
2. to have received upfront treatment with Cisplatin/Carboplatin, etoposide and anti PD1/PD-L1 inhibitors
3. No evidence of brain metastases at diagnosis
4. ECOG PS 0-2
5. adult patients (aged ≥ 18 years) at diagnosis;
6. signing of informed consent approved by the local Ethic Committee

Exclusion criteria

• none

Trial design

100 participants in 1 patient group

ES-SCLC

Description:

ES-SCLC receiving upfront chemo-immunotherapy

Treatment:

Drug: Atezolizumab